Followers | 3 |
Posts | 350 |
Boards Moderated | 0 |
Alias Born | 01/14/2010 |
Tuesday, May 26, 2015 7:13:19 AM
The world’s largest consumer goods company will on Tuesday launch a grant competition in Singapore, asking academics to submit research proposals on 3D bioprinting applications that would be relevant to P&G.
“We want to look at the possibilities of bioprinting. It’s definitely a very strong emerging area,” said Professor Elena Lurie-Luke, who heads up P&G’s Global Life Sciences Open Innovation business.
Bioprinting works by taking cultured human cells and forming a bio-ink, which is then placed into cartridges that contain a syringe fitted with an extrusion nozzle for printing.
The bioprinter deposits a pattern of cells in layers, interspersed with a water-based gel known as hydrogel that is used as a kind of scaffolding for the cells. The printed tissue is then left to grow naturally, and the hydrogel removed.
P&G is not the only company eyeing up the emerging technology. L’Oréal, the French cosmetics group, said earlier this month it was partnering with US bioprinting start-up Organovo to 3D print human skin.
L’Oréal already has a laboratory in Lyon, France, which focuses on producing in vitro skin tissue. It was set up in 2011 to expand L’Oréal’s use of the method as cosmetics companies began moving away from animal testing.
“We have a number of different in vitro skin models we’re working on because we are very involved in beauty care. If companies are doing innovation and interested in new tools then bioprinting should very much be on their horizon,” said Ms Lurie-Luke.
Bioprinting is also being looked at by pharmaceuticals companies as a way of speeding up and lowering the cost of drug development and testing. Organovo, the world’s first publicly traded 3D bioprinting company, has developed living liver tissue for medical and drug research and clinical trials.
Some experts believe it could also one day be used to produce replacement organs for patients desperately in need of a transplant — but this is unlikely to become a reality in the next 20 years.
While conventional 3D printing of plastics has been around since the 1980s, bioprinting is still in the early stages of development. The technology is currently being used for research, but a few companies — such as Organovo — are attempting to commercialise the production of bioprinted tissues.
3D printing helps to speed up the tissue-making process and make it more precise. Previously scaffolds were created by hand — or 3D printed — and then the cells were positioned using a handheld pipette.
P&G’s new grant is part of a five-year S$60m scheme with the Singapore government’s Agency for Science, Technology and Research. It is open to any of the country’s research institutes.
“There’s a lot of interest from both consumer goods companies and big pharma in bioprinting. P&G’s strategy to launch a grant competition is probably a very cost effective way of trying to get a snapshot of all the possibilities,” said Brian Derby, professor of materials science at the University of Manchester.
Recent ONVO News
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/09/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:05:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2023 11:05:02 AM
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results • GlobeNewswire Inc. • 12/06/2023 01:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/01/2023 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:41:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:40:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:34:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:32:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2023 09:41:04 PM
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/13/2023 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:34 PM
- Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/08/2023 01:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:05:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/22/2023 08:05:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2023 09:06:56 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM